CG Oncology, Inc. (CGON) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 177 institutional investors hold a position in CG Oncology, Inc. (NASDAQ:CGON).

• These investors collectively held 102.0% of the company's total shares outstanding in September 2025, up from 100.1% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by -1.49%, with a year-over-year an increase of 46.28% in the count of filers.
• The latest 13F cycle for CG Oncology reveals that of 177 total investors, 85 funds grew their exposure, whereas 62 reduced theirs and 30 made no changes.
• This class of investors decreased its holdings in CG Oncology to 77.75Mn shares for the 13F-cycle ending September 2025, down by 1.18Mn shares quarter on quarter, and up 25.57Mn shares year over year.
• With 6.58Mn shares, VANGUARD GROUP INC commands the largest institutional position in CG Oncology as of September 30, 2025, equating to 8.63% of the company.
• Among the most significant buyers of CG Oncology during September 2025 were WELLINGTON MANAGEMENT GROUP LLP (3.61Mn), VANGUARD GROUP INC (670.77K), Clearbridge Investments, LLC (613.85K), Candriam S.C.A. (274.31K), DIMENSIONAL FUND ADVISORS LP (193.14K).
• Leading sellers of CG Oncology stock in September 2025 included MARSHALL WACE, LLP (2.36Mn), MORGAN STANLEY (1.23Mn), BANK OF AMERICA CORP /DE/ (988.42K), CITADEL ADVISORS LLC (900.15K), MILLENNIUM MANAGEMENT LLC (706.79K).
• The top 10 institutional holders of CG Oncology for the quarter ending September 2025 included VANGUARD GROUP INC (6.58Mn), Decheng Capital LLC (6.37Mn), WELLINGTON MANAGEMENT GROUP LLP (5.51Mn), BlackRock, Inc. (4.59Mn), FMR LLC (3.87Mn), TCG Crossover Management, LLC (3.67Mn), BRAIDWELL LP (3.28Mn), Foresite Capital Management VI LLC (2.22Mn), ALLIANCEBERNSTEIN L.P. (2.14Mn), UBS Group AG (2.13Mn).